이경원

선택된 필터

전체 240건 중 91번부터 100번까지의 결과를 표시합니다.

2020

Article

Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?

Article

ADRIATIC: A Phase III Study with Durvalumab plus /- Tremelimumab after concurrent Radiochemotherapy for Patients with SCLC in Stage Limited Disease

Article

Prognostic role of extracellular vesicles in squamous cell carcinoma of the lung

Article

P2Y(2)R has a significant correlation with Notch-4 in patients with breast cancer

Article

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Article

A phase III, open-label, randomized study of atezolizumab in combination with carboplatin plus paclitaxel plus bevacizumab compared with pemetrexed plus cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).

Article

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

Article

Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Article

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

Article

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).

상세 보기

이경원

자료유형

발행연도

키워드

언어

선택된 필터

Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?

ADRIATIC: A Phase III Study with Durvalumab plus /- Tremelimumab after concurrent Radiochemotherapy for Patients with SCLC in Stage Limited Disease

Prognostic role of extracellular vesicles in squamous cell carcinoma of the lung

P2Y(2)R has a significant correlation with Notch-4 in patients with breast cancer

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).